Medication use and treatment patterns in children and adolescents with chronic tic disorders: an EMTICS study.

Authors

Orit Peled, Daphna Shoham, Tamar Steinberg, Alan Apter, Dana Feldman-Sadeh, Miri Carmel, Idan Barak, Zsanett Tarnok, Peter Nagy, Abraham Weizman, Pieter J Hoekstra, Andrea Dietrich, EMTICS collaborative group, Noa Benaroya-Milshtein

Published in

European child & adolescent psychiatry. Jul 17, 2026. Epub Jul 17, 2026.

Abstract

The treatment of tic disorders in children and adolescents poses significant challenges, especially when comorbid conditions such as obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) are present. Pharmacological treatments are often guided by clinical judgment, prescriber preferences, and medication availability. This study describes pharmacological treatment use in a large cohort of children and adolescents with chronic tic disorders (CTDs). We analyzed baseline data from the European Multicenter Tics in Children Study (EMTICS) to examine associations between medication use, tic severity, and psychiatric comorbidities, using parent-reported questionnaires and clinical interviews to assess tics, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and children's self-rated premonitory urges. Among 709 children aged 3-16 years with CTDs, 230 (32%) received any pharmacological treatment, 22% received antipsychotics and 10% received ADHD medications, with limited use of alpha-2 agonists (3%). Medication use was more common among individuals with comorbid ADHD (54%) than those with CTD only (23%) or comorbid OCD only (26%). Those on tic-suppressing medications had significantly greater severity of tics, tic-related impairment, and comorbid ADHD, ODD, and obsessive symptom severity compared to those with non-tic-suppressing medications. There was no relationship with the severity of compulsions or premonitory urges. While largely consistent with published guidelines, these findings indicate limited utilization of recommended agents, such as alpha-2 agonists, alongside higher reported symptom severity among those receiving tic-suppressing medications. Further studies should explore the integration of pharmacological, behavioral, and psychoeducational approaches tailored to comorbidity profiles and symptom severity.

PMID:
42467078
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.